Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg‐positive and HBeAg‐negative chronic hepatitis B
This study was aimed at comparing clinical applicability of serum HBsAg quantification in relation to intrahepatic covalently closed-circular DNA (cccDNA) in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon (PEG-IFN) monotherapy for 48 weeks. Overall, 32 and 36 patients with HBeAg-positive and HBeAg-negative CHB, respectively were recruited. Paired liver biopsies at baseline and end of therapy were analyzed for cccDNA. Virological response (VR) at 48 weeks post-treatment was defined as HBeAg clearance (for HBeAg-positive CHB) and HBV DNA <2,000IU/ml (for both groups). The results demonstrated that baseline levels of all viral markers were higher in the HBeAg-positive group than the HBeAg-negative group. Baseline HBsAg correlated with cccDNA in the HBeAg-positive group (r=0.452, P=0.009) but not in the HBeAg-negative group (r=0.018, P=0.919). However, the magnitude of cccDNA and HBsAg decline at end of treatment was not different between groups. The reduction of HBsAg showed a positive correlation with cccDNA decline in HBeAg-positive and HBeAg-negative CHB (r=0.544, P=0.001 and r=0.364, P=0.029, respectively). Overall, responders had more decline in cccDNA and HBsAg levels compared with non-responders. Patients with serum HBsAg decline of >1.0 log10IU/ml during treatment archived VR and HBsAg clearance of 80% and 30%, respectively. In conclusion, serum HBsAg represented a better surrogate marker of intrahepatic cccDNA in patients with HBeAg-positive CHB compared to those with HBeAg-negative CHB. On-treatment, HBsAg reduction of 1.0 log10IU/mL was associated with a high probability of subsequent VR and HBsAg clearance in patients receiving PEG-IFN therapy. J. Med. Virol. 89:130-138, 2017. © 2016 Wiley Periodicals, Inc..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
Journal of medical virology - 89(2017), 1, Seite 130-138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chuaypen, Natthaya [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
CccDNA |
| RVK: |
|---|
| doi: |
10.1002/jmv.24601 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1987073363 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1987073363 | ||
| 003 | DE-627 | ||
| 005 | 20230508064609.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.24601 |2 doi | |
| 028 | 5 | 2 | |a PQ20170301 |
| 035 | |a (DE-627)OLC1987073363 | ||
| 035 | |a (DE-599)GBVOLC1987073363 | ||
| 035 | |a (PRQ)p1571-18cfb4cb82efe4fd66af6c392bf90d6d441fc69a2ee939f3fcf1287dbdb3ddeb3 | ||
| 035 | |a (KEY)0015763520170000089000100130kineticsofserumhbsagandintrahepaticcccdnaduringpeg | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Chuaypen, Natthaya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg‐positive and HBeAg‐negative chronic hepatitis B |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a This study was aimed at comparing clinical applicability of serum HBsAg quantification in relation to intrahepatic covalently closed-circular DNA (cccDNA) in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon (PEG-IFN) monotherapy for 48 weeks. Overall, 32 and 36 patients with HBeAg-positive and HBeAg-negative CHB, respectively were recruited. Paired liver biopsies at baseline and end of therapy were analyzed for cccDNA. Virological response (VR) at 48 weeks post-treatment was defined as HBeAg clearance (for HBeAg-positive CHB) and HBV DNA <2,000IU/ml (for both groups). The results demonstrated that baseline levels of all viral markers were higher in the HBeAg-positive group than the HBeAg-negative group. Baseline HBsAg correlated with cccDNA in the HBeAg-positive group (r=0.452, P=0.009) but not in the HBeAg-negative group (r=0.018, P=0.919). However, the magnitude of cccDNA and HBsAg decline at end of treatment was not different between groups. The reduction of HBsAg showed a positive correlation with cccDNA decline in HBeAg-positive and HBeAg-negative CHB (r=0.544, P=0.001 and r=0.364, P=0.029, respectively). Overall, responders had more decline in cccDNA and HBsAg levels compared with non-responders. Patients with serum HBsAg decline of >1.0 log10IU/ml during treatment archived VR and HBsAg clearance of 80% and 30%, respectively. In conclusion, serum HBsAg represented a better surrogate marker of intrahepatic cccDNA in patients with HBeAg-positive CHB compared to those with HBeAg-negative CHB. On-treatment, HBsAg reduction of 1.0 log10IU/mL was associated with a high probability of subsequent VR and HBsAg clearance in patients receiving PEG-IFN therapy. J. Med. Virol. 89:130-138, 2017. © 2016 Wiley Periodicals, Inc. | ||
| 540 | |a Nutzungsrecht: © 2016 Wiley Periodicals, Inc. | ||
| 650 | 4 | |a HBsAg | |
| 650 | 4 | |a treatment response | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a pegylated‐interferon | |
| 650 | 4 | |a cccDNA | |
| 650 | 4 | |a Deoxyribonucleic acid--DNA | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Virology | |
| 650 | 4 | |a Interferon | |
| 650 | 4 | |a Kinetics | |
| 700 | 1 | |a Sriprapun, Methee |4 oth | |
| 700 | 1 | |a Praianantathavorn, Kesmanee |4 oth | |
| 700 | 1 | |a Payungporn, Sunchai |4 oth | |
| 700 | 1 | |a Wisedopas, Naruemon |4 oth | |
| 700 | 1 | |a Poovorawan, Yong |4 oth | |
| 700 | 1 | |a Tangkijvanich, Pisit |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d Hoboken, NJ : Wiley-Liss, 1977 |g 89(2017), 1, Seite 130-138 |w (DE-627)130482439 |w (DE-600)752392-0 |w (DE-576)016070275 |x 0146-6615 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2017 |g number:1 |g pages:130-138 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/jmv.24601 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1002/jmv.24601/abstract |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1834479211 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 89 |j 2017 |e 1 |h 130-138 | ||